To boost support for caregivers on an international scale, Merck KGaA of Darmstadt, Germany, launched a worldwide program called Embracing Carers and presented recent survey results at a conference in Australia.
Dupixent (dupilumab), a medication jointly marketed by Sanofi and Regeneron Pharmaceuticals for relieving a form of eczema known as atopic dermatitis (AD) in adults, recently received marketing approval in the European Union (EU).
With relatively little known about suicide from a genetic standpoint and its prevalence among youth fatalities in Utah, University of Utah Health has collaborated with Janssen Research & Development on the Utah Suicide Genetics Project.
A Phase 3 CHRONOS test from Sanofi and Regeneron Pharmaceuticals of the drug Dupixent shows promise in patients with uncontrolled moderate to severe atopic dermatitis when used with a topical corticosteroid.
Newly released results from an international Phase 3 clinical trial show Xultophy 100/3.6, a new treatment for diabetes developed by Novo Nordisk Inc. is more effective than traditional insulin alone and eliminates some insulin side effects.
Patients suffering from triple negative breast cancer, a treatment-resistant form of the disease, have a new option in pembrolizumab, a drug manufactured by Merck that was previously FDA-authorized for other malignancies.
Bristol-Myers Squibb said it will collaborate with Advaxis Inc. in a study to evaluate ADXS-DUAL and Opdivo (nivolumab) in a combination therapy for cervical cancer that has resisted or recurred after chemotherapy.
A Merck drug credited by strong Phase 3 clinical data for HIV-1 suppression despite its possibility of deadly skin side effects has been approved by the U.S. Food and Drug Administration for once-daily doses along with other antivirals.